Induction Therapy With Targeted Therapy Followed by Surgery for Stage IIIB and IV Non-small Cell Lung Cancer: a Multi-center, Single-arm, Prospective Clinical Study
Overview
- Phase
- Phase 2
- Intervention
- Osimertinib Mesylate
- Conditions
- Non Small Cell Lung Cancer
- Sponsor
- Wuhan Union Hospital, China
- Enrollment
- 30
- Primary Endpoint
- PFS
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of neoadjuvant targeted therapy followed by surgery in participants with advanced non-small cell lung cancer.
Detailed Description
Advanced non-small cell lung cancer (NSCLC) accounts for a high proportion of lung cancer cases. Targeted therapy improve the survival in these patients, but acquired drug resistance will inevitably occur. If tumor downstaging is achieved after targeted therapy, could surgical resection before drug resistance improve clinical benefits for patients with advanced NSCLC? Here, the investigators conducted a clinical trial showing that for patients with advanced driver gene mutant NSCLC who did not progress after targeted therapy, salvage surgery (SS) could improve progression-free survival (PFS).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pathological diagnosis of NSCLC with confirmed activation of driver gene mutation (EGFR mutant: exon 19 deletion or exon 21 L858R mutation; ALK-rearrangement) by amplification refractory mutation system (ARMS);
- •stage IIIB-IV according to the eighth edition of the American Joint Committee on Cancer staging system confirmed by pathological diagnosis and positron emission tomography-computed tomography (PET-CT) and biopsy
- •Written informed consent provided；
- •Age 18-70 when signing the consent form, both male and female;
- •The ECOG score is 0 or 1;
- •Adequate hematological function, liver function and renal function;
- •Female participants should not be pregnant or breast-feeding.
Exclusion Criteria
- •Previously received systemic anti-tumor therapy for non-small cell lung cancer;
- •Subjects who have received chest radiotherapy in the past;
- •Known human immunodeficiency virus (HIV) infection;
- •Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease);
- •Pregnancy or breast-feeding women;
- •Ingredients mixed with small cell lung cancer patients.
Arms & Interventions
targeted therapy+salvage surgery
Participants treated with targeted therapy without progression and radiological confirmation of tumor downstaging (≤stage IIIA) by PET-CT followed by salvage surgery were enrolled into the group of targeted therapy plus salvage surgery. The molecular targeted agents used in our study included osimertinib (80 mg, once a day) . Salvage surgery was defined as surgical intervention based on standard operation (lobectomy plus lymphadenectomy) of NSCLC for advanced patients who initially had no surgical indications, but achieved significant downstaging (≤stage IIIA) without progression after targeted therapy. Targeted therapy was continued after salvage surgery until progression.
Intervention: Osimertinib Mesylate
Outcomes
Primary Outcomes
PFS
Time Frame: 3 year
Progression-Free Survival
Secondary Outcomes
- OS(3 year)
- Resectability rate(1 year)